Pharmaceutical Giants Pilot New Research Tool
OpenAI Debuts GPT-Rosalind AI for Life Sciences
New specialized model aims to speed up drug discovery and biological research with partners Amgen and Moderna.
A digital DNA double helix glows on a computer screen inside a modern biotechnology laboratory where a scientist is working.
Photo: Kronos Digital News
OpenAI has launched GPT-Rosalind, its first artificial intelligence model specialized for the life sciences [1]. The new system aims to accelerate drug discovery and complex biological research [1][3]. Named after DNA pioneer Rosalind Franklin, the model helps scientists generate hypotheses and manage intricate scientific workflows [1]. Pharmaceutical leaders Amgen and Moderna are currently piloting the technology to streamline their research processes [1]. GPT-Rosalind enters a competitive field, positioning OpenAI against established research tools like Google’s AlphaFold [2]. The model focuses on processing vast biological datasets to support specialized medical innovation [2][3].
Editorial notes
Transparency note
Drafted with LLM; human-edited
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
Reviewed for sourcing quality and editorial consistency.
Sources
- 1.↗
cnet.com
https://www.cnet.com/tech/services-and-software/openai-gpt-rosalind-model-release/
- 2.↗
siliconrepublic.com
https://www.siliconrepublic.com/machines/openai-rival-google-alphafold-ai-model-life-sciences-research
- 3.↗
fiercebiotech.com
https://www.fiercebiotech.com/biotech/openai-launches-biotech-specific-ai-model-gpt-rosalind
Related stories
View all
Topics
About the author
Kronos Digital News Desk covers pharmaceutical giants pilot new research tool and editorial analysis for Kronos Digital News.